GWP.L Share News (GWP)

Earnings, Trading Statements Calendar - Week Ahead

GW Pharmaceuticals Sativex Trials Disappoint; Signs Deal In Australia

GW Pharma surges on positive results from schizophrenia drug trial

(ShareCast News) - Shares in GW Pharmaceuticals surged after the company announced positive top-line results from an exploratory Phase 2a placebo-controlled clinical trial of Cannabidiol (CBD) for the treatment of schizophrenia. GW said the 88 patients involved the trial had previously failed to res

GW Pharmaceuticals Gets Positive Results From Cannabidiol Trial

CORRECT: BROKER RATINGS SUMMARY: Liberum Cuts Weir Price Target

BROKER RATINGS SUMMARY: Liberum Cuts Weir Price Target, Repeats Sell

BUZZ-GW Pharmaceuticals Plc: Morgan Stanley starts with "overweight"

** U.S.-listed shares of UK-based maker of cannabis-derived drugs up 8.5 pct at $112.25 ** Morgan Stanley initiates with "overweight", $150 PT ** GW is considered the market leader in medical cannabis applications with key value driver Epidiolex, which is being tested in rare seizure

GW Pharmaceuticals pre-tax loss widens on R&D costs

(ShareCast News) - GW Pharmaceuticals posted a widening of its pre-tax loss for the nine months to the end of June as the company continues to invest heavily in its product pipeline. For the nine months ended 30 June, GW reported a pre-tax loss of $60.41m, wider than its $38.47m loss in the same per

UPDATE: GW Pharmaceuticals Loss Widens As It Progresses Trials

GW Pharmaceuticals Birth Asphyxia Conditions Treatment Gets Fast Track

Earnings, Trading Statements Calendar - Week Ahead

Earnings, Trading Statements Calendar - Week Ahead

Earnings, Trading Statements Calendar - Week Ahead

Earnings, Trading Statements Calendar - Week Ahead

Earnings, Trading Statements Calendar - Week Ahead